Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Advertisement
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Loss of inhibitor of kappa B epsilon was found to drive NF-κB pathway activity and migration and proliferation of CLL cells.
CAR T-cell therapies effectively treated patients with Richter transformation, an aggressive subtype of CLL.
Patients with Richter transformation had improved outcomes when treated with venetoclax-based treatment regimens.
Catherine Coombs, MD, outlined some of her research into the solid tumor microenvironment, particularly in prostate cancer.
Paolo Ghia, MD, PhD talks about his session on monoclonal B-cell lymphocytosis presented at the AACR Annual Meeting 2024.
Elias Jabbour, MD, discusses the latest news and novel therapies in CLL.
In patients with CLL, zanubrutinib showed advantages in PFS and CR rates with "potentially improved" OS.
Dr. Siddiqi shares data from the phase I/II TRANSCEND CLL 004 trial on liso-cel in patients with relapsed or refractory CLL.
Treatment with ibrutinib plus FCR followed by ibrutinib maintenance induced durable and deep responses in patients with CLL.
The CAR-T therapy was approved based on response rate and duration of response data from the TRANSCEND CLL 004 trial.
The researchers developed CAR T-cells that target and eliminate mutated CLL cells while sparing healthy B-cells.
Acalabrutinib with or without obinutuzumab had sustained safety and efficacy in patients with CLL in six years of follow-up.
NX-2127, a first-in-class therapy, induced BTK degradation and clinical responses in CLL resistant to BTK inhibitors.
MRD-directed ibrutinib plus venetoclax therapy improved PFS in patients with CLL.
The study defined mutations that develop resistance to BTK inhibitors and evaluated the BTK degrader NX-2127 in CLL.
The presence of two or more mutations are associated with high-risk cell features.
Chaitra Ujjani, MD, discusses research on the incidence and management of COVID-19 infections in patients with CLL.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
Section Editor
Alexey V. Danilov, MD, PhDCo-Director of the Toni Stephenson Lymphoma Center | City of Hope National Medical Center
Advertisement
